Caroline Seymour | Authors


Ipatasertib, Paclitaxel Combo Does Not Improve PFS in PIK3CA/AKT1/PTEN-Altered TNBC

December 11, 2020

Treatment with ipatasertib plus paclitaxel (Abraxane) failed to show a significant improvement in progression-free survival versus placebo plus paclitaxel in patients with PIK3CA/AKT1/PTEN-altered locally advanced, unresectable, or metastatic triple-negative breast cancer.

Alpelisib/Letrozole Combo Sustains Efficacy in PIK3CA-Mutant HR+, HER2- Advanced Breast Cancer

December 11, 2020

Combination treatment with alpelisib (Piqray) and letrozole (Femara) sustained efficacy and did not result in any new safety signals in patients with PIK3CA-mutant HR-positive, HER2-negative advanced breast cancer who received prior treatment with the combination of a CDK4/6 inhibitor and fulvestrant (Faslodex).

Phase 3 EMPOWER-Lung 1 Shows Promise for Cemiplimab-rwlc in Advanced PD-L1+ NSCLC

September 23, 2020

Cemiplimab-rwlc (Libtayo) monotherapy led to a significant improvement in overall survival and progression-free survival in patients with advanced non-small cell lung cancer with PD-L1 expression on at least 50% of their tumor cells.